2019 Volume 35 Issue 2 Pages 119-124
Background: Percutaneous transcatheter closure of perimembranous ventricular septal defects (PMVSD) is becoming increasingly common. However, in Japan, surgical closure is the only curative treatment currently available.
Methods: We retrospectively analyzed the age, weight, and laboratory data of patients with VSD who had been evaluated at our department between September 2007 and August 2016. Using eligibility criteria for safe closure based on previous reports, we identified the patients eligible for percutaneous closure with the Amplatzer duct occluder I (ADO I) were identified.
Results: Of the 359 patients included in the study, VSD in 102 patients spontaneously closed and that in 121 patients required surgical closure. VSD in 136 patients did not close and the patients were followed-up without closure. Of these 136 patients, 101 had PMVSD, of whom 21 met eligibility criteria for percutaneous closure using the ADO I.
Conclusion: Our results suggest that among the patients who were followed-up without closure, a certain percentage of patients meet the criteria for percutaneous closure. Numerous patients with VSD may benefit from minimally-invasive percutaneous closure if it is introduced in Japan.
